Company: NDRA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001654954-25-003612
Chunk: 446

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 2
Chunk 446
---
  $97,583,906  $5,233  $(91,930,152) $5,658,989 

Year Ended December 31, 2024  Series A Convertible  Series B Convertible             Total    Preferred Stock  Preferred Stock  Common stock  Additional    Accumulated  Stockholders’   Shares   Amount  Shares   Amount  Shares   Amount  Paid in Capital  Stock Payable  Deficit  Equity Balance as of December 31, 2023   141.397  $1   -  $-   5,937  $1  $97,583,906  $5,233  $(91,930,152) $5,658,989 Preferred stock conversion to common stock  (123.909)  (1)  -   -   5   -   1   -   -   - Common stock issued for cash  -   -   -   -   3,671   -   1,148,470   -   -   1,148,470 Common stock issued for warrant exercise  -   -   -   -   520,922   52   5,368,312   -   -   5,368,364 Common stock issued for cashless warrant exercise  -   -   -       6,327   -   1,320,567   -   -   1,320,567 Fair value of vested common stock  -   -   -   -   46   -   80,000   -   -   80,000 Fair value of vested stock options  -   -   -   -   -   -   491,924   -   -   491,924 Stock payable towards preference dividend  -   -   -   -   -   -   5,233   (5,233)  -   - Net loss  -   -   -   -   -